Development and Analysis of a Stool Bank for Cancer Patients

Summary

This study is aimed at understanding the impact of gut microbiota on efficacy of cancer therapies, in particular checkpoint inhibitors, and using the resulting information to design microbial immunotherapies. Although animal models are of use to determine the influences of gut and other microbiota on cancer treatment modalities, they are limited due to differences between mouse and human physiology and immunology, as well as the inherent differences in gut microbial populations between the two mammalian organisms. Therefore, samples obtained as donations from human subjects undergoing cancer treatment are of great value for the identification and determination of bacteria and their metabolic processes that are involved in the successful cure and remission of cancer by checkpoint inhibitor therapies. The objective of this study is to collect 3 samples each of blood, urine, and stool in subjects with cancer. This is a non-interventional, 2 site study in 100 people who are undergoing any type of cancer immunotherapy. Subjects who meet the entry criteria will provide 5 samples each of blood, urine, and stool over a 12-month period.

Eligibility

Inclusion Criteria:

* Men or women who are ≥ 18 years old who are undergoing any type of cancer immunotherapy
* Subjects who are able to provide written informed consent

Exclusion Criteria:

* Subjects with HIV, Hepatitis B, or Hepatitis C
* Subjects without the mental capacity to complete either a written or online questionnaire, alone or with assistance, or make sound decisions
* Women who are pregnant or who plan on becoming pregnant
* Women who are nursing

Conditions4

Interventions1

Locations2 sites

Find trials near these locations

Related trials

• Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery — UNICANCER
• Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK — Hunan Province Tumor Hospital
• Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) — University of Alabama at Birmingham
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 — Summit Therapeutics
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients — Summit Therapeutics
• Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer — CJ Bioscience, Inc.
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors — Hefei TG ImmunoPharma Co., Ltd.

Browse More Trials